Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SNB 101

Next Previous
Drug Profile

SNB 101

Alternative Names: SN-38 - SN BioScience; SNB-101

Latest Information Update: 17 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SN BioScience
  • Class Antineoplastics; Camptothecins; Indolizines; Pyrans; Quinolines; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Small cell lung cancer; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Small cell lung cancer
  • Phase I Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 09 Mar 2026 Phase-I/II clinical trials in Small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Metastatic disease) in Serbia (IV) (NCT07391813)
  • 06 Feb 2026 SN BioScience plans a phase I/II trial for Small-cell lung cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) (IV) in February 2026 (NCT07391813)
  • 10 Dec 2025 SNB 101 receives Orphan Drug status for Gastric cancer in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top